VHL-deficient vasculogenesis in hemangioblastoma

Sven Gläsker, Jonathan Smith, Mark Raffeld, Jie Li, Edward H. Oldfield, Alexander O. Vortmeyer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Hemangioblasts are capable of differentiation into vascular structures and blood. Patients with von Hippel-Lindau (VHL) disease develop hemangioblastomas which are composed of VHL-deficient tumor cells with protracted hemangioblastic differentiation potential. In a subset of these tumors, hemangioblastic differentiation is characterized by different stages of red blood cell formation. It has remained controversial, however, whether VHL-deficient hemangioblastic cells are similarly capable of differentiating into vascular cells and functioning vascular structures in vivo.By histologic, immunohistologic and microdissection-based genetic analysis of 60 VHL disease-associated hemangioblastomas, we re-examined the controversial question whether VHL-deficient neoplastic hemangioblastic cells are capable of vascular differentiation (vasculogenesis).In most tumors (n= 47), there was no evidence of either vasculogenesis or hematopoiesis; tumor cells were either scattered between reactive angiogenetic vascular structures or arranged in solid clusters. A subset of tumors (n= 13), however, revealed vaculogenetic structures that were composed of cuboidal or flat cells and frequently contained red blood cell precursors or mature red blood cells. Microdissection-based deletion analysis of epithelial cells confirmed them to be VHL-deficient tumor cells. Immunohistochemistry for CD31 was consistently negative in these structures, and no evidence could be obtained for connectivity with reactive vasculature.We demonstrate that hemangioblastic differentiation capacity of VHL-deficient hemangioblastic cells includes not only erythropoiesis, but also differentiation into primitive vasculogenetic structures. Tumor cells, however, do not appear to have the potential of terminal differentiation into mature and functional vascular structures.

Original languageEnglish (US)
Pages (from-to)162-167
Number of pages6
JournalExperimental and Molecular Pathology
Volume96
Issue number2
DOIs
StatePublished - Apr 1 2014

Fingerprint

Hemangioblastoma
Tumors
Cells
Blood Vessels
Microdissection
Blood
Neoplasms
von Hippel-Lindau Disease
Erythrocytes
Hemangioblasts
Erythropoiesis
Hematopoiesis
Epithelial Cells
Immunohistochemistry

Keywords

  • Angiogenesis
  • Hemangioblastoma
  • Vasculogenesis
  • Von Hippel-Lindau disease

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

VHL-deficient vasculogenesis in hemangioblastoma. / Gläsker, Sven; Smith, Jonathan; Raffeld, Mark; Li, Jie; Oldfield, Edward H.; Vortmeyer, Alexander O.

In: Experimental and Molecular Pathology, Vol. 96, No. 2, 01.04.2014, p. 162-167.

Research output: Contribution to journalArticle

Gläsker, S, Smith, J, Raffeld, M, Li, J, Oldfield, EH & Vortmeyer, AO 2014, 'VHL-deficient vasculogenesis in hemangioblastoma', Experimental and Molecular Pathology, vol. 96, no. 2, pp. 162-167. https://doi.org/10.1016/j.yexmp.2013.12.011
Gläsker, Sven ; Smith, Jonathan ; Raffeld, Mark ; Li, Jie ; Oldfield, Edward H. ; Vortmeyer, Alexander O. / VHL-deficient vasculogenesis in hemangioblastoma. In: Experimental and Molecular Pathology. 2014 ; Vol. 96, No. 2. pp. 162-167.
@article{7c951ea045b64f4a933afa361ec3e967,
title = "VHL-deficient vasculogenesis in hemangioblastoma",
abstract = "Hemangioblasts are capable of differentiation into vascular structures and blood. Patients with von Hippel-Lindau (VHL) disease develop hemangioblastomas which are composed of VHL-deficient tumor cells with protracted hemangioblastic differentiation potential. In a subset of these tumors, hemangioblastic differentiation is characterized by different stages of red blood cell formation. It has remained controversial, however, whether VHL-deficient hemangioblastic cells are similarly capable of differentiating into vascular cells and functioning vascular structures in vivo.By histologic, immunohistologic and microdissection-based genetic analysis of 60 VHL disease-associated hemangioblastomas, we re-examined the controversial question whether VHL-deficient neoplastic hemangioblastic cells are capable of vascular differentiation (vasculogenesis).In most tumors (n= 47), there was no evidence of either vasculogenesis or hematopoiesis; tumor cells were either scattered between reactive angiogenetic vascular structures or arranged in solid clusters. A subset of tumors (n= 13), however, revealed vaculogenetic structures that were composed of cuboidal or flat cells and frequently contained red blood cell precursors or mature red blood cells. Microdissection-based deletion analysis of epithelial cells confirmed them to be VHL-deficient tumor cells. Immunohistochemistry for CD31 was consistently negative in these structures, and no evidence could be obtained for connectivity with reactive vasculature.We demonstrate that hemangioblastic differentiation capacity of VHL-deficient hemangioblastic cells includes not only erythropoiesis, but also differentiation into primitive vasculogenetic structures. Tumor cells, however, do not appear to have the potential of terminal differentiation into mature and functional vascular structures.",
keywords = "Angiogenesis, Hemangioblastoma, Vasculogenesis, Von Hippel-Lindau disease",
author = "Sven Gl{\"a}sker and Jonathan Smith and Mark Raffeld and Jie Li and Oldfield, {Edward H.} and Vortmeyer, {Alexander O.}",
year = "2014",
month = "4",
day = "1",
doi = "10.1016/j.yexmp.2013.12.011",
language = "English (US)",
volume = "96",
pages = "162--167",
journal = "Experimental and Molecular Pathology",
issn = "0014-4800",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - VHL-deficient vasculogenesis in hemangioblastoma

AU - Gläsker, Sven

AU - Smith, Jonathan

AU - Raffeld, Mark

AU - Li, Jie

AU - Oldfield, Edward H.

AU - Vortmeyer, Alexander O.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Hemangioblasts are capable of differentiation into vascular structures and blood. Patients with von Hippel-Lindau (VHL) disease develop hemangioblastomas which are composed of VHL-deficient tumor cells with protracted hemangioblastic differentiation potential. In a subset of these tumors, hemangioblastic differentiation is characterized by different stages of red blood cell formation. It has remained controversial, however, whether VHL-deficient hemangioblastic cells are similarly capable of differentiating into vascular cells and functioning vascular structures in vivo.By histologic, immunohistologic and microdissection-based genetic analysis of 60 VHL disease-associated hemangioblastomas, we re-examined the controversial question whether VHL-deficient neoplastic hemangioblastic cells are capable of vascular differentiation (vasculogenesis).In most tumors (n= 47), there was no evidence of either vasculogenesis or hematopoiesis; tumor cells were either scattered between reactive angiogenetic vascular structures or arranged in solid clusters. A subset of tumors (n= 13), however, revealed vaculogenetic structures that were composed of cuboidal or flat cells and frequently contained red blood cell precursors or mature red blood cells. Microdissection-based deletion analysis of epithelial cells confirmed them to be VHL-deficient tumor cells. Immunohistochemistry for CD31 was consistently negative in these structures, and no evidence could be obtained for connectivity with reactive vasculature.We demonstrate that hemangioblastic differentiation capacity of VHL-deficient hemangioblastic cells includes not only erythropoiesis, but also differentiation into primitive vasculogenetic structures. Tumor cells, however, do not appear to have the potential of terminal differentiation into mature and functional vascular structures.

AB - Hemangioblasts are capable of differentiation into vascular structures and blood. Patients with von Hippel-Lindau (VHL) disease develop hemangioblastomas which are composed of VHL-deficient tumor cells with protracted hemangioblastic differentiation potential. In a subset of these tumors, hemangioblastic differentiation is characterized by different stages of red blood cell formation. It has remained controversial, however, whether VHL-deficient hemangioblastic cells are similarly capable of differentiating into vascular cells and functioning vascular structures in vivo.By histologic, immunohistologic and microdissection-based genetic analysis of 60 VHL disease-associated hemangioblastomas, we re-examined the controversial question whether VHL-deficient neoplastic hemangioblastic cells are capable of vascular differentiation (vasculogenesis).In most tumors (n= 47), there was no evidence of either vasculogenesis or hematopoiesis; tumor cells were either scattered between reactive angiogenetic vascular structures or arranged in solid clusters. A subset of tumors (n= 13), however, revealed vaculogenetic structures that were composed of cuboidal or flat cells and frequently contained red blood cell precursors or mature red blood cells. Microdissection-based deletion analysis of epithelial cells confirmed them to be VHL-deficient tumor cells. Immunohistochemistry for CD31 was consistently negative in these structures, and no evidence could be obtained for connectivity with reactive vasculature.We demonstrate that hemangioblastic differentiation capacity of VHL-deficient hemangioblastic cells includes not only erythropoiesis, but also differentiation into primitive vasculogenetic structures. Tumor cells, however, do not appear to have the potential of terminal differentiation into mature and functional vascular structures.

KW - Angiogenesis

KW - Hemangioblastoma

KW - Vasculogenesis

KW - Von Hippel-Lindau disease

UR - http://www.scopus.com/inward/record.url?scp=84894086328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894086328&partnerID=8YFLogxK

U2 - 10.1016/j.yexmp.2013.12.011

DO - 10.1016/j.yexmp.2013.12.011

M3 - Article

C2 - 24394472

AN - SCOPUS:84894086328

VL - 96

SP - 162

EP - 167

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

SN - 0014-4800

IS - 2

ER -